Home / Science / A UCLA Scoping Review Maps the Evidence Base for Six Recovery Peptides

bpc-157tb-500research-reviewsports-medicinesafetyevidence

A UCLA Scoping Review Maps the Evidence Base for Six Recovery Peptides

August 23, 2026

The most useful reviews in peptide research are usually the ones that report on the shape of the evidence rather than on any single result. A scoping review published online on 11 August 2026 in the American Journal of Sports Medicine, from a team in the Department of Orthopaedic Surgery at the David Geffen School of Medicine at UCLA, does exactly that for six peptides that circulate in recovery and performance contexts. Two of them, BPC-157 and TB-500, are catalogued on this site.

How the review was assembled

The authors used a scoping-review design and followed PRISMA reporting guidelines. They searched PubMed using permutations of six compound names — BPC-157, TB-500 (thymosin beta-4), CJC-1295, MK-677 (ibutamoren), ipamorelin and GHK-Cu — crossed with musculoskeletal tissue terms including bone, fracture, muscle, tendon, ligament, meniscus and cartilage. Three reviewers worked independently, with two screening each paper and a third acting as tiebreaker.

That structure matters. A prespecified search protocol commits the authors in advance to what counts as an eligible study, which makes the resulting picture of the literature reproducible rather than curated. It also means the composition of the result set is itself a finding.

What the literature actually consists of

The structural headline is that roughly 67% of the publications identified were preclinical animal studies, most commonly in rats. Within those models, the authors report that each compound showed its own distinct mechanism, with promising but variable effects on tendon, muscle, bone and ligament healing.

The variability is worth sitting with. Inconsistent results across rodent models of the same tissue are not necessarily a sign that a compound does nothing; they can also reflect differences in injury model, timing, or delivery. But they do mean that a single favorable rodent study is a weak basis for generalization, which is the position much of the BPC-157 and TB-500 literature currently occupies.

The human evidence is small and loosely controlled

Human clinical studies numbered only a handful across all six compounds, and the review characterizes most of them as lacking robust controls or rigorous study design. Where human results did exist, they were heterogeneous, and the authors describe the improvements as modest at best, concentrated in metabolic bone health and degenerative knee pain rather than in the broad recovery outcomes these compounds are often associated with.

The review also flags substantial heterogeneity in the amounts and administration routes used across the studies it screened. That heterogeneity is a methodological problem in its own right: when protocols differ that widely, results from one paper cannot be read straightforwardly against another.

The review does not treat unstudied as harmless

One of the more pointed contributions here is that the authors document specific risks rather than simply noting an absence of data. Across the group they identify cardiovascular complications and metabolic dysfunction such as insulin resistance, and they single out MK-677 as having been associated with congestive heart failure in the reported literature. MK-677 is not a compound supplied on this site, but its inclusion illustrates the point the review is making: the peptides grouped together under a single marketing category have meaningfully different risk profiles, and grouping them obscures that.

Two independent reviews, one conclusion

Onvytal covered a narrative review in Sports Medicine earlier this month that reached a broadly similar verdict on the gap between preclinical promise and human evidence. The UCLA paper arrives at that assessment by a different route — a prespecified search and structured screening rather than a narrative survey — and covers a partially different set of compounds. Two independent teams converging from different methodologies carries more weight than either paper on its own.

What this means for research on BPC-157 and TB-500

For anyone working with these compounds in a laboratory setting, the review functions as a map of where the literature is dense and where it is sparse. The dense regions are rodent tendon, ligament and bone-healing models; the sparse region is controlled human investigation, and that gap has not closed.

The authors’ own conclusion is directed at clinicians: they state that peptide supplements should not currently be recommended as a replacement for, or adjunct to, existing orthopaedic standard of care, on the grounds that robust efficacy and safety data are lacking. That is a statement about the state of the evidence, and it is consistent with how these materials are supplied here — as research compounds for qualified professionals, not as therapeutics.